Advanced urothelial cancer: a radiology update

被引：4
作者：
Alessandrino, Francesco [1 ,2 ]
Ghaith, Ola [1 ,2 ]
Williams, Kristin [1 ,2 ]
Sonpavde, Guru P. [3 ]
Silverman, Stuart G. [2 ]
Shinagare, Atul B. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
来源：
ABDOMINAL RADIOLOGY | 2019年 / 44卷 / 12期
关键词：
Urothelial carcinoma; Transitional cell; Urinary bladder neoplasms; Computed tomography; X-ray; Programmed cell death-1 receptor; Neoplasm; Metastasis; INVASIVE BLADDER-CANCER; CISPLATIN-INELIGIBLE PATIENTS; SOLID TUMORS; METASTATIC PATTERN; RESPONSE CRITERIA; ADVERSE EVENTS; SINGLE-ARM; OPEN-LABEL; CARCINOMA; CT;
D O I：
10.1007/s00261-019-02148-3
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The recent genomic characterization of urothelial carcinoma by the Cancer Genome Atlas Project, made possible by the introduction of high throughput, reduced cost, and sequence analysis, has shed new insights on the biology of advanced disease. In addition, studies on imaging of advanced urothelial carcinoma have widened the knowledge on disease presentation and on pattern of metastatic spread and their correlation with the underlying biology of urothelial carcinoma. The wide range of treatments for advanced urothelial cancer, including combined chemotherapy regimens and immune checkpoint inhibitors, each result in treatment class-specific patterns of response and adverse events. Results of studies point to the need for a reliable biomarker, perhaps with imaging, that predicts prognosis and treatment response to systemic treatment, and can be used to select the most effective treatment while minimizing toxicity. This review of advanced urothelial cancer introduces the latest advances in genetic profiling, the current role of imaging, the radiographic appearance of treatment response and their toxicities, and details potential future areas of imaging research.
引用
收藏
页码：3858 / 3873
页数：16
相关论文
共 100 条
[1]   Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors [J].
Adjei, AA .
ANNALS OF ONCOLOGY, 2000, 11 (10) :1335-1341
[2]   Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors [J].
Alessandrino, Francesco ;
Gujrathi, Rahul ;
Nassar, Amin H. ;
Alzaghal, Arwa ;
Ravi, Arvind ;
McGregor, Bradley ;
Sonpavde, Guru ;
Shinagare, Atul B. .
EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05) :680-686
[3]   Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor [J].
Alessandrino, Francesco ;
Sahu, Sonia ;
Nishino, Mizuki ;
Adeni, Anika E. ;
Tirumani, Sree Harsha ;
Shinagare, Atul B. ;
Awad, Mark M. .
ABDOMINAL RADIOLOGY, 2019, 44 (05) :1917-1927
[4]   Multimodality imaging of endocrine immune related adverse events: a primer for radiologists [J].
Alessandrino, Francesco ;
Shah, Hina J. ;
Ramaiya, Nikhil H. .
CLINICAL IMAGING, 2018, 50 :96-103
[5]   Neurologic complications of bladder carcinoma - A review of 359 cases [J].
Anderson, TS ;
Regine, WF ;
Kryscio, R ;
Patchell, RA .
CANCER, 2003, 97 (09) :2267-2272
[6]   Methotrexate-induced pulmonary injury: Serial CT findings [J].
Arakawa, H ;
Yamasaki, M ;
Kurihara, Y ;
Yamada, H ;
Nakajima, Y .
JOURNAL OF THORACIC IMAGING, 2003, 18 (04) :231-236
[7]   The evolution of bladder cancer genomics: What have we learned and how can we use it? [J].
Audenet, Francois ;
Attalla, Kyrollis ;
Sfakianos, John P. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (07) :313-320
[8]   First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].
Balar, Arjun V. ;
Castellano, Daniel ;
O'Donnell, Peter H. ;
Grivas, Petros ;
Vuky, Jacqueline ;
Powles, Thomas ;
Plimack, Elizabeth R. ;
Hahn, Noah M. ;
de Wit, Ronald ;
Pang, Lei ;
Savage, Mary J. ;
Perini, Rodolfo F. ;
Keefe, Stephen M. ;
Bajorin, Dean ;
Bellmunt, Joaquim .
LANCET ONCOLOGY, 2017, 18 (11) :1483-1492
[9]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[10]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
12345678910